Orion Corporation

    205 Aufrufe 205 0 Kommentare 0 Kommentare

    Managers’ transactions – Niclas Lindstedt

    ORION CORPORATION
    MANAGERS’ TRANSACTIONS
    21 AUGUST 2024 at 18.45 EEST
            

    Orion Corporation: Managers’ transactions – Niclas Lindstedt

    Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

    Orion Oyj - Managers' Transactions
    ____________________________________________
    Person subject to the notification requirement
    Name: Niclas Lindstedt
    Position: Other senior manager
    Issuer: Orion Oyj
    LEI: 74370029VAHCXDR7B745
    Notification type: INITIAL NOTIFICATION
    Reference number: 74920/9/8

    ____________________________________________
    Transaction date: 2024-08-20
    Venue: NASDAQ HELSINKI LTD (XHEL)
    Instrument type: SHARE
    ISIN: FI0009014377
    Nature of transaction: DISPOSAL

    Transaction details
    (1): Volume: 614 Unit price: 46.7 EUR
    (2): Volume: 521 Unit price: 46.7 EUR
    (3): Volume: 200 Unit price: 46.7 EUR
    (4): Volume: 200 Unit price: 46.7 EUR
    (5): Volume: 100 Unit price: 46.7 EUR
    (6): Volume: 125 Unit price: 46.7 EUR
    (7): Volume: 100 Unit price: 46.7 EUR
    (8): Volume: 125 Unit price: 46.7 EUR
    (9): Volume: 8 Unit price: 46.7 EUR
    (10): Volume: 5 Unit price: 46.7 EUR
    (11): Volume: 2 Unit price: 46.7 EUR

    Aggregated transactions (11):
    Volume: 2000 Volume weighted average price: 46.7 EUR

    Orion Corporation

    Liisa Hurme

    President and CEO
        Olli Huotari

    SVP, Corporate Functions
     

                                                    

    Publisher:
    Orion Corporation
    Communications
    Orionintie 1A, FI-02200 Espoo, Finland
    http://www.orion.fi/en
    http://www.twitter.com/OrionCorpIR

    Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Orion Corporation Managers’ transactions – Niclas Lindstedt ORION CORPORATION MANAGERS’ TRANSACTIONS 21 AUGUST 2024 at 18.45 EEST         Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, …